Discounted Cash Flow Calculation for SWX:ALC using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
SWX:ALC DCF 1st Stage: Next 10 year cash flow forecast
Amount off the current price
is available for.
Share price is
vs Future cash flow value of
Current Discount Checks
to be considered undervalued it must be available for at least 20% below the
current price. Less than 40% is even better.
Alcon's share price is below the future cash flow value, but not at a moderate discount (< 20%).
Alcon's share price is below the future cash flow value, but not at a substantial discount (< 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Alcon's earnings available for a low price, and how does
this compare to other companies in the same industry?
Alcon's earnings are expected to grow significantly at over 20% yearly.
Alcon's revenue is expected to grow by 5.2% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Alcon's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. David J. Endicott had been the Chief Executive Officer of Alcon at Novartis AG since July 1, 2018 until April 2019. Mr. Endicott has been the President of Hospira Medical Devices at Hospira Inc. since March 10, 2014. Mr. Endicott served as a Corporate Vice President and President of Allergan Medical, Asia Pacific and Latin America at Allergan Inc. since April 2011. He served as Corporate Vice President and President of Allergan Medical at Allergan, Inc. since August 2010. He served as Corporate Vice President and President of Europe, Africa and Middle East at Allergan, Inc. from October 2004 to August 2010 and managed the expansion of Allergan's business internationally, including Allergan's entry into new markets such as Turkey and Poland. He served as Senior Vice President of U.S. Specialty Pharmaceuticals from January 2004 to October 2004, Vice President and General Manager of Canada from February 2000 to December 2003 and Vice President of U.S. Managed Markets since 1998. He served as a Director of ZELTIQ Aesthetics, Inc. since April 25, 2016 until April 28, 2017. He served various roles at Allergan since joining Allergan Medical in 1986. He served as a Director of Orexigen Therapeutics, Inc. since November 30, 2012 until July 27, 2018. Mr. Endicott earned his Bachelor's Degree in Chemistry from Whitman College, his Master's in Business Administration from the University of Southern California and is a Graduate of the Harvard Business School Advanced Management Program.
Insufficient data for David to compare compensation growth.
Insufficient data for David to establish whether their remuneration is reasonable compared to companies of similar size in Switzerland.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Alcon management team is about average.
Senior Vice President of Human Resources
Senior Vice President of Global Manufacturing and Technical Operations
Chief Executive Officer
Chief Financial Officer
Chief Operating Officer and Executive Vice President
Senior VP & Chief Information Officer
Senior VP and Head of Global Investor Relations & Communications
Senior VP & General Counsel
Global Head of Communications and Vice President
Region President for North America
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Alcon board of directors is about average.
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The company also provides pharmaceutical products for elevated intraocular pressure caused by glaucoma; anti-inflammatories; anti-infective to aid in the treatment of bacterial infections and bacterial conjunctivitis; ophthalmic solutions to treat inflammation and pain associated with ocular surgery; eye inflammation and infection solutions following cataract surgery; and vitreomacular adhesion, eye and nasal allergy treatment solutions, and over-the-counter dry eye relief and ocular vitamins. In addition, it offers vision care products, such as contact lenses and lens care products; daily disposable, monthly replacement, and color-enhancing contact lenses for comfortable and convenient vision correction options; contact lens care products; multi-purpose and hydrogen-peroxide based solutions to clean, rinse, and disinfect contact lenses; rewetting drops; and daily protein removers that removes protein deposits from lenses. Alcon, Inc. was formerly known as Alcon Universal S.A. and changed the name to Alcon, Inc. in December 2001. The company was founded in 1945 and is based in Fort Worth, Texas. Alcon, Inc. was previously operating as a subsidiary of Novartis AG. Alcon, Inc.(SWX:ALC) operates independently of Novartis AG as of April 9, 2019.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.